Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: an analysis of integrated delivery network electronic health records

Table 4 Sensitivity analyses summary (uUTI patients with susceptible or not-susceptible isolates) [29]

Sensitivity analysis	Sample size	Difference [not-susceptible–susceptible] (P-value)
		Probability of progressing to cUTI		All-cause costs		UTI-related costs		All-cause costs (winsorized)		UTI-related costs (winsorized)
		Difference	P-value	Difference	P-value	Difference	P-value	Difference	P-value	Difference	P-value
Baseline	1009	+ 0.060	< 0.001*	+ 430.9	0.125	+ 184.3	0.144	+ 425.7	0.031*	+ 156.8	0.034*
#1 (strict exclusion)	661	+ 0.039	0.009*	+ 797.7	0.014*	+ 304.6	0.043*	+ 653.5	0.002*	+ 217.5	0.028*
#2 (loose exclusion)	1009	+ 0.060	< 0.001*	+ 430.9	0.125	+ 184.3	0.144	+ 425.7	0.031*	+ 156.8	0.034*
#3 (30-day follow-up)	1200	+ 0.057	< 0.001*	− 12.85	0.910	+ 17.57	0.877	+ 36.00	0.614	+ 22.65	0.555
#4 (360-day follow-up)	834	+ 0.058	< 0.001*	+ 412.2	0.285	+ 126.7	0.409	+ 301.9	0.256	+ 65.25	0.478
#5 (infectious disease exclusion)	955	+ 0.058	< 0.001*	+ 511.7	0.060	+ 206.5	0.085	+ 471.7	0.012*	+ 73.15	0.139
#6 (FQ-only)	166	+ 0.036	0.387	+ 605.8	0.316	+ 186.3	0.471	+ 484.9	0.307	+ 196.0	0.369

Shafrin J. Progression of an uncomplicated urinary tract infection among female patients with susceptible and non-susceptible urine isolates: findings from an integrated delivery network. [Oral] presented at IDWeek; September 29–October 3, 2021; Virtual event. https://idweek.org [29]
^*Statistically significant (P-value < 0.05)
cUTI complicated urinary tract infection, FQ fluoroquinolones, UTI urinary tract infection, uUTI uncomplicated urinary tract infection

ISSN: 2047-2994